In the evolving landscape of Medicare insurance, new research from Brown University’s School of Public Health sheds critical light on the burgeoning role and financial impact of brokers within the Medicare Advantage marketplace. This investigative study, recently published in JAMA Internal Medicine, reveals that payments to brokers facilitating Medicare Advantage enrollments have more than doubled in less than a decade, escalating from approximately $3.9 billion in 2014 to a staggering $10 billion by 2022. This dramatic increase signifies a notable shift in how private insurers allocate commission expenses towards these intermediaries, underscoring an urgent need to reevaluate the implications of such spending on taxpayers and beneficiaries alike.
At the forefront of this research is David Meyers, an associate professor specializing in health services, policy, and practice. His team’s analysis offers the first comprehensive national quantification of brokers’ involvement in Medicare Advantage enrollment processes and the concomitant financial flows directed toward their compensation. Their findings portray a complex and opaque insurance broker market, stimulating conversations about the alignment—or misalignment—between broker incentives, insurer priorities, and beneficiary welfare in the context of America’s rapidly expanding managed care sector.
Medicare Advantage plans, presented as alternatives to traditional Medicare, are offered by private insurers who rely heavily on brokers to guide millions of older Americans through complex coverage options. These brokers perform critical functions such as comparing available plans, elucidating benefits, and facilitating enrollment. However, the commissions they garner are paid directly by insurance companies, rather than beneficiaries or the government, raising pivotal concerns regarding objective guidance and the potential for broker bias influenced by financial incentives from insurers.
The research team obtained proprietary data through a Freedom of Information Act request, a rare glimpse behind the curtains of private insurer broker payments. Their data-driven exploration documents that broker utilization among first-time Medicare Advantage enrollees grew from 36% in 2014 to 44% in 2022, signaling a steady upward trajectory in dependence on brokers for plan selection and enrollment services. This rising trend corresponds with the substantial financial outlay seen in broker commissions, which warrants closer regulatory and policy scrutiny.
One of the study’s most unexpected outcomes is the prevalent role of renewals—beneficiaries continuing their existing Medicare Advantage plans—in driving broker spending. Instead of initial enrollment commissions being the primary cost factor, 70% of beneficiaries in Medicare Advantage generated renewal commissions by 2022, representing 74% of all broker-related payments. This finding reveals that a significant portion of broker income is derived not from assisting new plan selections but from recurring fees associated with the status quo.
These renewal-driven commissions imply that brokers may be compensated disproportionately for maintaining existing enrollee relationships, rather than actively supporting beneficiaries in making informed and optimal choices annually. Meyers emphasizes the potentially problematic nature of this dynamic, where brokers receive compensation “not for helping a beneficiary make an active choice” but for “collecting on that choice after the fact.” This trend raises questions about whether broker incentives strongly align with beneficiaries’ evolving healthcare needs or simply perpetuate ongoing revenue streams.
The implications of this expanding broker market extend beyond mere expenditures, touching upon fundamental concerns related to conflicts of interest and beneficiary outcomes. Meyers and colleagues caution that brokers, often beholden to the insurers paying their commissions, may steer seniors towards plans offering higher broker remuneration rather than those best suited to individual health needs. The lack of transparent data around the specific commission structures for different plans further complicates the capacity to evaluate these potential misalignments comprehensively.
While the study’s broad estimate of $10 billion annually in broker commissions might be inflated if some insurers pay less than the federal maximum, it could also be a conservative figure, as it excludes significant bonus payments tied to enrollment targets that insurers routinely provide brokers. This dual uncertainty highlights the opaque nature of broker compensation and the critical need for more granular disclosures and analyses to fully understand the financial ecosystem underwriting broker behavior in Medicare Advantage.
Medicare Advantage plans now constitute coverage for over half of all Medicare beneficiaries—a staggering demographic representation—and their continuous expansion means broker influence over a substantial portion of America’s senior healthcare decisions is only growing. Despite attempts by the Centers for Medicare and Medicaid Services (CMS) to regulate broker compensation and attenuate potential perverse incentives, these efforts were recently nullified in federal court, leaving the current system largely unchecked and perpetuating uncertainty about the appropriateness of existing compensation practices.
Health economists and policymakers alike face mounting pressure to generate evidence evaluating whether broker-assisted enrollments correlate with better health outcomes or increased beneficiary satisfaction. Meyers notes that despite the vast sums allocated to broker commissions, “it’s really not clear what we’re buying,” underscoring the necessity for rigorous outcome-focused research to determine the true value delivered by brokers in this complex market.
The Brown University study ultimately flags the Medicare Advantage broker market as a critical, yet understudied aspect of healthcare policy deserving urgent inquiry. The public expenditure on these intermediary services stems fundamentally from U.S. taxpayers, amplifying the societal stake in ensuring broker services deliver genuine value rather than acting solely as revenue conduits for insurers. Until such clarifying research emerges, the ongoing exponential growth in broker payments compels policymakers, regulators, and the public to scrutinize the system more intensely.
With Medicare Advantage continuously reshaping the healthcare coverage landscape for millions of seniors, this new analysis provides a vital foundation for future reforms aimed at transparency, alignment of incentives, and enhanced accountability. The compelling revelation that broker compensation is driven predominantly by renewals rather than active consumer choice highlights gaps in oversight that could have substantial ramifications for affordability and equitable access to optimal care plans in the United States.
As the healthcare community grapples with these findings, one thing remains clear: improving understanding of the broker market’s economics and influence is essential before further policy or regulatory interventions can be responsibly designed. The Brown University team’s pioneering work marks a critical first step toward addressing these systemic challenges in Medicare Advantage, holding promise for advancing fairness and efficiency in one of the nation’s largest public-private insurance programs.
Subject of Research: Trends in Broker Enrollment and Spending in Medicare Advantage
Article Title: Trends in Broker Enrollment and Spending in Medicare Advantage
News Publication Date: 18-May-2026
Web References:
10.1001/jamainternmed.2026.0864
Keywords: Health and medicine, Health care costs, Health care delivery, Health care policy
